Doravirine plus dolutegravir switch for people with HIV
Treatments studied
Part of Infections clinical trials.
This Phase 3 study tests whether switching from a three-drug HIV regimen to a two-drug regimen (doravirine plus dolutegravir) can keep your virus levels controlled. It may help people who are stable on their current treatment explore a simpler switch under close monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and have HIV-1
- You’ve been on a stable, suppressive three-drug HIV treatment for at least 6 months
- You do not have known resistance to doravirine (DOR) or dolutegravir (DTG)
- Your recent labs are safe enough: hemoglobin at least 9, platelets at least 80, and kidney function (creatinine clearance) at least 30
- You are not pregnant or breastfeeding
- If you’re able to become pregnant, you use reliable birth control as required by the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two HIV medicines, doravirine and dolutegravir, to see which works better for people who have never taken HIV treatment before. If you qualify, you would be randomly assigned to one of the two medications.
This trial is for people with HIV who are not responding well to the drug dolutegravir (DTG). It tests if switching to a different drug, darunavir/ritonavir (DRV/r), works better than continuing DTG when resistance has developed.
This trial compares a two-drug regimen of doravirine and lamivudine to another two-drug regimen of dolutegravir and lamivudine for people with HIV who have had a suppressed viral load for at least 24 months. The goal is to see if the newer combination works as well as the current one.
This study looks at switching your current HIV medication to a two-drug combination pill called dolutegravir/lamivudine (DTG/3TC). The goal is to see if this simpler regimen is safe and effective for people who are also on opioid agonist therapy. If you qualify, you may have the option to switch to a potentially easier HIV treatment while continuing your opioid therapy.
This trial tests better ways to manage HIV when the virus becomes resistant to dolutegravir (DTG), a key medicine. It is for people with high viral load despite being on DTG for at least six months.
This study tests a fast-start HIV treatment using doravirine, tenofovir, and lamivudine for people who were just diagnosed with HIV in the last 30 days and have never taken HIV medications before. The goal is to see if starting treatment right away is safe and effective.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.